Skip to main content

Bevyxxa Disease Interactions

There are 4 disease interactions with Bevyxxa (betrixaban).

Major

Betrixaban (applies to Bevyxxa) bleeding

Major Potential Hazard, Moderate plausibility.

The use of betrixaban is contraindicated in patients with active pathological bleeding. Care and close monitoring is recommended when using this agent in patients who are receiving neuraxial anesthesia or undergoing spinal puncture as epidural or spinal hematomas may occur. Consider risk of using this agent when scheduling patients for spinal procedures.

References

  1. (2017) "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals
Major

Betrixaban (applies to Bevyxxa) hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of betrixaban is not recommended in patients with hepatic impairment as these patients may have intrinsic coagulation abnormalities.

References

  1. (2017) "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals
Major

Betrixaban (applies to Bevyxxa) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Patients with severe renal impairment (CrCl >= 15 to < 30 mL/min computed by Cockcroft-Gault using actual body weight) may have an increased risk of bleeding events. It is recommended to reduce the betrixaban dose in patients with severe renal impairment. Monitor patients closely and promptly evaluate any signs or symptoms of blood loss in these patients. No dose adjustment is needed for mild or moderate renal impairment (CrCl > 30 mL/min, computed by Cockcroft-Gault using actual body weight).

References

  1. (2017) "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals
Moderate

Oral anticoagulants (applies to Bevyxxa) antiphospholipid syndrome

Moderate Potential Hazard, Moderate plausibility.

Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS). Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.

References

  1. (2010) "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim
  2. (2022) "Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals, SUPPL-39
  3. (2021) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb, SUPPL-34
  4. (2021) "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc., SUPPL-17
View all 4 references

Bevyxxa drug interactions

There are 277 drug interactions with Bevyxxa (betrixaban).

Bevyxxa alcohol/food interactions

There is 1 alcohol/food interaction with Bevyxxa (betrixaban).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer